tetano
Editor, Senior Moderator
Oncologist
. 2022 Mar 28;oyac038.
doi: 10.1093/oncolo/oyac038. Online ahead of print.
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
Hala T Borno[SUP] 1 2 [/SUP], Mi-Ok Kim[SUP] 2 3 [/SUP], Julian C Hong[SUP] 2 4 5 [/SUP], Sasha Yousefi[SUP] 4 5 [/SUP], Amy Lin[SUP] 1 2 [/SUP], Irina Tolstykh[SUP] 3 [/SUP], Sylvia Zhang[SUP] 2 [/SUP], Rana R McKay[SUP] 6 7 [/SUP], Olivier Harismendy[SUP] 7 8 [/SUP], Pelin Cinar[SUP] 1 2 [/SUP], Hope Rugo[SUP] 1 2 [/SUP], Vadim S Koshkin[SUP] 1 2 [/SUP], Maya Rabow[SUP] 9 [/SUP], Christine Wang[SUP] 10 [/SUP], Adina Bailey[SUP] 1 [/SUP], Eric J Small[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: The risks associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated illness, coronavirus disease 2019 (COVID-19), among patients with a cancer diagnosis have not been fully characterized. This study leverages data from a multi-institutional cohort study, the University of California Cancer COVID Consortium, to evaluate outcomes associated with SARS-CoV-2 infection among patients with cancer.
Methods: Clinical data were collected from March to November 2020 and included patient demographics, cancer history and treatment, SARS-CoV-2 exposure and testing, and COVID-19 clinical management and outcomes. Multivariate ordinal logistic regression permitting unequal slopes was used to evaluate the impact of demographic, disease, and treatment factors on SARS-CoV-2 related hospitalization, intensive care unit (ICU) admission, and mortality.
Findings: Among all evaluated patients (n = 303), 147 (48%) were male, 118 (29%) were older adults (≥65 years old), and 104 (34%) were non-Hispanic white. A subset (n = 63, 21%) had hematologic malignancies and the remaining had solid tumors. Patients were hospitalized for acute care (n = 79, 26%), ICU-level care (n = 28, 9%), or died (n = 21, 7%) due to COVID-19. Patients with ≥2 comorbidities were more likely to require acute care (odds ratio [OR] 2.09 [95% confidence interval (CI), 1.23-3.55]). Cough was identified as a significant predictor of ICU hospitalization (OR 2.16 [95% CI, 1.03-4.57]). Importantly, mortality was associated with an active cancer diagnosis (OR 3.64 [95% CI, 1.40-9.5]) or advanced age (OR 3.86 [95% CI, 1.2-12.44]).
Interpretation: This study observed that patients with active cancer or advanced age are at an increased risk of death from COVID-19. These study observations can inform risk counseling related to COVID-19 for patients with a cancer diagnosis.
Keywords: COVID-19; cancer; mortality.
. 2022 Mar 28;oyac038.
doi: 10.1093/oncolo/oyac038. Online ahead of print.
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
Hala T Borno[SUP] 1 2 [/SUP], Mi-Ok Kim[SUP] 2 3 [/SUP], Julian C Hong[SUP] 2 4 5 [/SUP], Sasha Yousefi[SUP] 4 5 [/SUP], Amy Lin[SUP] 1 2 [/SUP], Irina Tolstykh[SUP] 3 [/SUP], Sylvia Zhang[SUP] 2 [/SUP], Rana R McKay[SUP] 6 7 [/SUP], Olivier Harismendy[SUP] 7 8 [/SUP], Pelin Cinar[SUP] 1 2 [/SUP], Hope Rugo[SUP] 1 2 [/SUP], Vadim S Koshkin[SUP] 1 2 [/SUP], Maya Rabow[SUP] 9 [/SUP], Christine Wang[SUP] 10 [/SUP], Adina Bailey[SUP] 1 [/SUP], Eric J Small[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35348771
- DOI: 10.1093/oncolo/oyac038
Abstract
Background: The risks associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated illness, coronavirus disease 2019 (COVID-19), among patients with a cancer diagnosis have not been fully characterized. This study leverages data from a multi-institutional cohort study, the University of California Cancer COVID Consortium, to evaluate outcomes associated with SARS-CoV-2 infection among patients with cancer.
Methods: Clinical data were collected from March to November 2020 and included patient demographics, cancer history and treatment, SARS-CoV-2 exposure and testing, and COVID-19 clinical management and outcomes. Multivariate ordinal logistic regression permitting unequal slopes was used to evaluate the impact of demographic, disease, and treatment factors on SARS-CoV-2 related hospitalization, intensive care unit (ICU) admission, and mortality.
Findings: Among all evaluated patients (n = 303), 147 (48%) were male, 118 (29%) were older adults (≥65 years old), and 104 (34%) were non-Hispanic white. A subset (n = 63, 21%) had hematologic malignancies and the remaining had solid tumors. Patients were hospitalized for acute care (n = 79, 26%), ICU-level care (n = 28, 9%), or died (n = 21, 7%) due to COVID-19. Patients with ≥2 comorbidities were more likely to require acute care (odds ratio [OR] 2.09 [95% confidence interval (CI), 1.23-3.55]). Cough was identified as a significant predictor of ICU hospitalization (OR 2.16 [95% CI, 1.03-4.57]). Importantly, mortality was associated with an active cancer diagnosis (OR 3.64 [95% CI, 1.40-9.5]) or advanced age (OR 3.86 [95% CI, 1.2-12.44]).
Interpretation: This study observed that patients with active cancer or advanced age are at an increased risk of death from COVID-19. These study observations can inform risk counseling related to COVID-19 for patients with a cancer diagnosis.
Keywords: COVID-19; cancer; mortality.